ArticleThe clinical respiratory journal2026
Diagnostic and Clinical Value of Targeted Next-Generation Sequencing for Pediatric Respiratory Infections in Northern China.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric patients are particularly susceptible to respiratory tract infections (RTIs) due to ongoing maturation of pulmonary and immune function, highlighting the need for rapid and accurate pathogen identification. Although targeted next-generation sequencing (tNGS) is increasingly applied in infectious disease diagnostics, its real-world clinical utility in pediatric RTIs remains underexplored.
methodsWe conducted a retrospective study of 940 hospitalized children with RTIs in northern China between April and December 2023. All patients underwent tNGS alongside conventional microbiological tests (CMTs), including PCR, culture, and serology. Diagnostic performance metrics-including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)-were calculated. The clinical impact of tNGS was assessed by examining treatment adjustments, turnaround time (TAT), and patient outcomes.
resultstNGS demonstrated superior diagnostic performance compared with CMTs: sensitivity 91.38% versus 29.68%, specificity 91.03% versus 90.17%, PPV 97.68% versus 77.78%, and NPV 73.39% versus 54.60%. tNGS identified a broader spectrum of pathogens, including RNA viruses and low-abundance organisms frequently missed by CMTs, and detected polymicrobial infections in 17.77% of cases versus 1.17% by CMTs. Based on tNGS, treatment was escalated in 35.32% and de-escalated in 29.04% of patients, with over 90% of adjustments made within 48 h, facilitated by a mean TAT of 28.5 h. Clinical improvement was observed in most adjusted cases. Pathogen distribution showed age- and season-specific patterns, underscoring the need for context-informed diagnostics and therapy.
conclusiontNGS enhances pathogen detection accuracy in pediatric RTIs, enables timely and appropriate treatment modifications, and supports antimicrobial stewardship. Its high sensitivity, rapid TAT, and capacity to identify co-infections reinforce its clinical utility in guiding optimized management of pediatric respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.